Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01339871|
Recruitment Status : Completed
First Posted : April 21, 2011
Last Update Posted : June 16, 2017
|Condition or disease||Intervention/treatment||Phase|
|Advanced Cancer||Drug: Pazopanib Drug: Vorinostat||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||152 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies|
|Actual Study Start Date :||April 20, 2011|
|Primary Completion Date :||June 7, 2017|
|Study Completion Date :||June 7, 2017|
Experimental: Pazopanib + Vorinostat
Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily
Starting dose 400 mg orally daily of 28 day cycle.
Other Name: GW786034Drug: Vorinostat
Starting dose 100 mg orally daily of 28 day cycle.
- Maximum tolerated dose (MTD) of Pazopanib and Vorinostat [ Time Frame: 28 days ]Maximum tolerated dose defined by dose limiting toxicities (DLTs) that occur in the first 28 days. . Non-hematological toxicities are graded by using NCI CTCAE v4.0 toxicity criteria and DLT defined as treatment-related grade 3 or greater non-hematological toxicity other than nausea, vomiting, fatigue, or hypertension, drug-related grade 3 or greater electrolyte abnormalities that do not return to ≤ grade 1 or baseline within 72 hours, grade 3 nausea and vomiting related to study drug treatment that is not controlled at 72 hours despite appropriate antiemetic therapy, or grade 4 fatigue or hypertension related to study drug therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01339871
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Siqing Fu, MD,PHD||M.D. Anderson Cancer Center|